A Phase 2 interventional study of Pregabalin and Placebo in Alcohol Use Disorder, sponsored by New York State Psychiatric Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by New York State Psychiatric Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Alcoholism by New York State Psychiatric Institute — 1 open to participants now, 1 under way, none of them phase 3. Alcoholism · New York State Psychiatric Institute.
Among the 18 studies in Alcoholism by New York State Psychiatric Institute, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 17th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →1 of the 18 studies in Alcoholism by New York State Psychiatric Institute is open now, in 1 country. Recruiting first, the newest first:
New York State Psychiatric Institute · Sites in United States
Ages 21–70
By country, each count listing its studies:
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 2 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 34 across the 16 interventional studies, 368 across the 2 observational. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
New York State Psychiatric Institute is the lead sponsor of 436 studies on the registry; 28 are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 46 (88%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Alcoholism by New York State Psychiatric Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In a 10-week randomized double-blind placebo-controlled outpatient pilot trial the efficacy of pregabalin in the treatment of alcohol dependence will be studied in 50 treatment-seeking outpatients. Participants will report drinking a minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week over the past 28 days.
In a 10-week double-blind placebo controlled outpatient clinical trial, the safety and efficacy ofpregabalin will be tested in 50 outpatients with Alcohol Use Disorder.Participants will be randomly allocated (1:1) to receive pregabalin or an identical-appearing, inert placebo. All study medication (placebo and pregabalin) will be over-capsulated with riboflavin to assess compliance. Pregabalin will be administered in 75 mg and 100 capsules; placebo capsules will appear identical to the pregabalin capsules. Participants in both study arms will receive the same number of capsules. Pregabalin will be titrated over a 3-week period to the FDA maximum (600 mg per day) or the maximum tolerated dose.
Study visits will occur daily for the first 4 days of the study period, then approximately every other day for the remainder of week 1, for a total of 5 study visits (study days 1,2,3,4, and 5 or 7). During the second week, study visits will continue every other day for a total of 3 study visits (study days 8,10, and 12). During the remainder of the 8-week medication study period, study visits will occur twice weekly. There will be two visits during a post-study taper week (week 9) and a follow-up visit during week 10. One visit per week will be with the research psychiatrist. All participants will have a weekly supportive behavioral treatment session with the research psychiatrist using a manual designed for pharmacotherapy trials in subjects with alcohol use disorders
Due to a federally mandated, institution-wide pause in research activities under our Federal Wide Assurance (FWA) this study was paused on 6/23/2026.
A best interest continuation for participants enrolled when paused was received and the last participant completed on 07/13/2023 IO removed pause on 03/20/2026 Received IRB approval to lift suspension 03/27/2026 NYSPI institutional approval to proceed with research and data analysis was granted on 04/07/2026
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.
Drug: Pregabalin
Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.
Other: Placebo
Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
Also known as: Lyrica
Placebo capsules will be provided twice daily over 8 weeks and one week taper..
Change in Proportion of Heavy Drinking Days Over Time
Change in heavy drinking days as quantified by the proportion of heavy drinking (HDD) days (defined as any day where the number of standard drinks was at least 5 for men and at least 4 for women) per week as measured by the timeline follow-back (TLFB) method.
Time frame: measured weekly over the 8 weeks of the medication phase of the trial or length of each individual's participation
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 22 | 21 |
| Completed | 14 | 13 |
| Not completed | 8 | 8 |
Change in heavy drinking days as quantified by the proportion of heavy drinking (HDD) days (defined as any day where the number of standard drinks was at least 5 for men and at least 4 for women) per week as measured by the timeline follow-back (TLFB) method.
| percentage of HDD days per week | Pregabalin | Placebo |
|---|---|---|
| Week 1 | 51.7 (36.2 to 66.9) | 59.5 (42.2 to 74.7) |
| Week 8 | 37.0 (22.3 to 54.5) | 46.7 (29.2 to 65.1) |
Collected over Over the course of the 10 week trial.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | 0/22 (0%) | 0/22 (0%) | 21/22 (95.5%) |
| Placebo | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| increased blood pressureCardiac disorders | 11/22 | 7/21 |
| tachycardiaCardiac disorders | 5/22 | 2/21 |
| anxietyPsychiatric disorders | 4/22 | 4/21 |
| depressionPsychiatric disorders | 4/22 | 4/21 |
| dizzinessGeneral disorders | 4/22 | 1/21 |
| drowsinessGeneral disorders | 4/22 | 2/21 |
| chest painGeneral disorders | 0/22 | 3/21 |
| dry mouthGeneral disorders | 3/22 | 2/21 |
| fatigueGeneral disorders | 3/22 | 1/21 |
| nauseaGastrointestinal disorders | 3/22 | 1/21 |
| Age, Continuous(years) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Mean | 44.4 ± 11.6 | 48.2 ± 9.7 | 46.3 ± 10.8 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 16 | 15 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 16 | 15 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 9 |
| White | 12 | 12 | 24 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results published in this report (after de-identification) (text, tables, figures)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: beginning 12 months and ending 5 years after article publication
Access criteria: to researcher who provides a methodologically sound proposal to achieve aims in the approved proposal
Ran from Jan 2021 to primary completion in Jul 2023, 30 months.
Results were first posted in Nov 2026, 3 years 3 months after primary completion.
Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's 30 months is below that.
Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jun 2025 → Jul 2023 and completion Jun 2025 → Jul 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
New York State Psychiatric Institute →